Mark Bodmer - 01 Nov 2023 Form 4 Insider Report for Evelo Biosciences, Inc.

Role
CSO, President of R&D
Signature
/s/ Marella Thorell, Attorney-in-Fact for Mark Bodmer
Issuer symbol
EVLO on OTC
Transactions as of
01 Nov 2023
Net transactions value
-$2,262
Form type
4
Filing time
03 Nov 2023, 16:12:23 UTC
Previous filing
13 Sep 2023
Next filing
08 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVLO Common Stock Options Exercise +12,500 +75% 29,124 01 Nov 2023 Direct F1
transaction EVLO Common Stock Sale $2,262 -6,854 -24% $0.3300 22,270 02 Nov 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Restricted Stock Units Options Exercise $0 -12,500 -33% $0.000000 25,000 01 Nov 2023 Common Stock 12,500 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $0.31 to $0.33, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F4 The RSUs vest in three (3) substantially equal installments on each of November 1, 2023, February 1, 2024 and May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. These RSUs have no expiration date.